Leerink Partners Upgrades Abbott Laboratories Amid Positive MedTech Outlook
Leerink Partners has upgraded Abbott Laboratories (ABT) from 'Market Perform' to 'Outperform,' signaling growing confidence in the medical technology sector. The upgrade is driven by expectations that the MedTech industry will deliver significant returns over the next 12 to 24 months. The analyst suggests that multiple macroeconomic and industry-specific factors are positioning MedTech companies for outsized performance through 2027. This shift reflects a bullish sentiment regarding the sector's growth trajectory and Abbott's specific position within it.

Tickers: $ABT
Topics: MedTech sector Stock upgrade